NASDAQ : APMD
Apnimed, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 16.4 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 682.74M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 637.78M |
| Enterprise Value | 555.36M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 41.63M |
| Shares Outstanding | 41.63M |
| Shares Change (YoY) | +562.85% |
| Shares Change (QoQ) | -24.89% |
| Owned by Insiders (%) | 1.27% |
| Owned by Institutions (%) | 22.91% |
| Float | 20.46M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 1.80 |
| Forward PE | n/a |
| PS Ratio | 5.46 |
| Forward PS | 1,256.42 |
| PB Ratio | 9.01 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 3.34 |
| EV / Sales | 4.74 |
| EV / EBITDA | 15.20 |
| EV / EBIT | 15.22 |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 5.19 |
| Quick Ratio | 4.88 |
| Debt / Equity | 1.30 |
| Debt / EBITDA | 2.49 |
| Debt / FCF | n/a |
| Interest Coverage | 12.61 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 22.44% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $1.42M |
| Profits Per Employee | $2.02M |
| Employee Count | 81 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 22.68 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 31.92 |
| Average Volume (20 Days) | 382,776 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 1.80M |
| Short Previous Month | 1.76M |
| Short % of Shares Out | 4.33% |
| Short % of Float | 8.82% |
| Short Ratio (days to cover) | 2.78 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 115.12M |
| Gross Profit | 108.10M |
| Operating Income | 35.87M |
| Pretax Income | 170.74M |
| Net Income | 163.58M |
| EBITDA | 35.90M |
| EBIT | 35.87M |
| Earnings Per Share (EPS) | $8.49 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 172.80M |
| Total Debt | 90.39M |
| Net Cash | 82.42M |
| Net Cash Per Share | $1.98 |
| Equity (Book Value) | 69.76M |
| Book Value Per Share | -36.69 |
| Working Capital | 149.19M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -69.94M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 27,000 |
| Net Borrowing | 83.19M |
| Free Cash Flow | -69.94M |
| FCF Per Share | -$1.68 |
Margins
| Measure | Value |
|---|
| Gross Margin | 93.90% |
| Operating Margin | 31.16% |
| Pretax Margin | 148.32% |
| Profit Margin | 142.10% |
| EBITDA Margin | 31.18% |
| EBIT Margin | 31.16% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -562.85% |
| Shareholder Yield | -562.85% |
| Earnings Yield | 55.43% |
| FCF Yield | -11.13% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $50.33 |
| Price Target Difference | 228.53% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 55.46% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 0.65 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |